Online inquiry

IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10822MR)

This product GTTS-WQ10822MR is a type of mRNA modified with 5-Methyl-CTP & Pseudo-UTP, which ecodes the monoclonal antibody that targets PD-L1; TGFBR2 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001267706.2; NM_001024847.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126; 7048
UniProt ID Q9NZQ7; P37173
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10822MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3214MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ARGX-110
GTTS-WQ13405MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PRO132365
GTTS-WQ8931MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IL-1 Trap
GTTS-WQ11427MR IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MEDI-8897
GTTS-WQ12759MR IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-52M51
GTTS-WQ4477MR IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-931699
GTTS-WQ2260MR IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ALX-0171
GTTS-WQ180MR IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 12-IgG1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW